Abivax's data for its experimental ulcerative colitis treatment shows improved safety and better efficacy and should reassure investors, Stifel analysts write. Negative side effects in the trial were limited, with no new concerns raised. Evidence from the trial supports a favorable benefit-to-risk profile ahead of the company's submission of the drug to regulators in the fourth quarter of 2026, the analysts say. The drug also performed well among patients with difficult-to-treat ulcerative colitis, suggesting more patients could benefit from the drug than previously thought, the analysts note. Paris-listed Abivax shares surge 30%, leading Europe's Stoxx 600. (josephmichael.stonor@wsj.com)